- Open Access
HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
Journal of Hematology & Oncology volume 5, Article number: 57 (2012)
Lymphomas frequently retain wild-type (wt) p53 function but overexpress HDM2, thereby compromising p53 activity. Therefore, lymphoma is a suitable model for studying the therapeutic value of disrupting the HDM2-p53 interaction by small-molecule inhibitors (SMIs). HDM2 have been developed and are under various stages of preclinical and clinical investigation. Previously, we examined the anti-lymphoma activity of MI-319, the laboratory grade of a new class of HDM2 SMI, the spiro-oxindole, in follicular lymphoma. Since then, MI-219, the clinical grade has become readily available. This study further examines the preclinical effects and mechanisms of MI-219 in a panel of human lymphoma cell lines as well as a cohort of patient-derived B-lymphcytes for its potential clinical use.
Preclinical assessment of MI-219 was evaluated by means of an in vitro and ex vivo approach and compared to Nutlin-3, the gold standard. Characterization of p53 activity and stability were assessed by quantitative PCR, Western blot, and immunoprecipitation. Biological outcome was measured using Trypan blue exclusion assay, Annexin V/PI, PARP and caspase-3 cleavage. Surprisingly, the overall biological effects of Nutlin-3 were more delayed (48 h) while MI-219 triggered an earlier response (12-24 h), predominantly in the form of apoptotic cell death. Using a cell free autoubiquitination assay, neither agent interfered with HDM2 E3 ligase function. MI-219 was more effective in upregulating wt-p53 stabilization compared to Nutlin-3. MI-219, but not Nutlin-3, enhanced the autoubiquitination and degradation of HDM2.
Our data reveals unexpected differences between MI-219 and the well-studied Nutlin-3 in lymphoma cell lines and patient samples. We suggest a novel mechanism for MI-219 that alters the functional activity of HDM2 through enhanced autoubiquitination and degradation. Additionally, this mechanism appears to correspond to biological outcome. Our results provide evidence that different classes of HDM2 SMIs elicit molecular events that extend beyond HDM2-p53 dissociation which may be of biological and potentially therapeutic importance.
The estimated number of newly diagnosed non-Hodgkin’s lymphoma cases for 2012 is expected to be 70,130 of which 18,940 patients (27%) will fail to survive. This represents a 9.89% increase in diagnosed cases compared to that estimated in 2007. While the expected mortality has marginally decreased from 29.5% in 2007 to 27% in 2012, there is reason for optimism but no reason to celebrate until a complete cure is found [1, 2]. Unlike solid tumors which could be treated in situ or removed if diagnosed early, lymphoma cells circulate alongside with normal lymphocytes making treatment options limited. However, the inherent defects within the cells that initiate transformation of normal cells into cancer are similar, as are the mechanisms evading cell death and development of resistance.
One of the most recognized defects is altered functionality of p53, the protein product of the TP53 gene . p53, often considered guardian of genome, is a master transcriptional regulator at the center of complex molecular networks controlling cell proliferation and death. Therefore, the integrity of functional wild-type p53 (wt-p53) tumor suppressor activity is a vital component of normal cellular homeostasis and protection from cancer development. p53 is activated in response to multiple stress signals and activated p53 induces genes involved in biological outcomes such as apoptosis, cell cycle arrest, DNA repair, senescence, and more recently, metabolism [4–6]. Deregulation of p53 by inactivating mutations occurs in approximately 50% of all human cancers, impairing DNA binding and transcription of tumor suppressive target genes . Tumors that possess a mutant p53 (mt-p53) have been shown to evade apoptosis, resist many therapeutic interventions, and exhibit qualities associated with poor prognosis [8–11]. Therefore, maintaining functional wt-p53 activity is central to favorable treatment outcomes in cancer.
Numerous posttranslational mechanisms exist to control p53 activity and ultimately determine its cellular fate. HDM2 (Human Double Minute 2) is a RING finger E3-ubiquitin ligase that acts as the predominant negative regulator of p53. HDM2 is also a transcriptional target gene of p53, creating an autoregulatory feedback loop that regulates p53 activity and stability. HDM2 binds to p53, inactivates its transcriptional activity and facilitates ubiquitin-dependent degradation of p53 by exporting it out of the nucleus [12–14]. Furthermore, p53-independent functions of HDM2 exist and may be influenced through interaction with additional proteins . In addition to its role in regulating functional p53 activity, HDM2 is also capable of self-regulation via autoubiquitination and is thought to degrade itself by means of the proteasome [16, 17]. Although this self-regulatory function of HDM2 is well-documented, the control and activation of this function still remains highly elusive. Importantly, HDM2 destabilization is required for proper p53 response. In fact, an early step in the accumulation of p53 in response to stress, DNA damage in particular, is an associated increase in HDM2 autoubiquitination and degradation [18, 19].
Overexpression of HDM2 has been shown to facilitate cancer development and progression in several tumor types and is often found in hematological malignancies. It is observevd more frequently in low grade non-Hodgkin’s lymphomas (NHL) (56.5%) than in aggressive NHL (10.8%), with HDM2 elevated even further in patients with advanced clinical stage . Abnormal expression of HDM2 has also been detected in Hodgkin lymphomas (HL) . However, little is known about the prognostic value of HDM2 in lymphomas. Several non-genotoxic small-molecule inhibitors (SMIs) have been developed to block HDM2-p53 with attempts to restore tumor suppressive activity to tumor cells with wt-p53. This is an attractive therapeutic strategy , particularly in lymphomas, where p53 mutations account for less than 15% of all cases [23, 24], yet wt-p53 remains dysfunctional due to overexpressed HDM2.
Although preclinical assessment of several HDM2 SMIs have demonstrated great promise, it is becoming increasingly clear that multiple molecular mechanisms modulate their anti-cancer efficacy in conjunction with genetic components of the patient’s tumor. More importantly, novel HDM2 SMIs are currently under clinical evaluation in phase I studies, demonstrating the significant impact and clinical relevance of these agents . We previously reported the anti-lymphoma effects of a laboratory grade spiro-oxindole MI-319, in our established WSU-FSCCL cell line and xenograft model . Since then, the clinical grade MI-219 has become readily available. In this study, we assessed the preclinical potential of MI-219 and re-examined selected molecular consequences associated with HDM2 inhibition in lymphoma cell lines and a cohort of malignant patient-derived B-lymphocytes. Our data uncovers unexpected differences between MI-219 compared to archetypical Nutlin-3. The results suggest a crucial role of mediating enhanced HDM2 activity towards itself, in conjunction with wt-p53 reactivation, which affects MI-219 sensitivity in this tumor type. More in-depth understanding of how HDM2 SMIs impact the myriad of biological processes conducted by p53 in lymphoma cells is necessary in order to in maximize their therapeutic exploitation.
Characteristics of patient sample
To extend our findings previously investigated , we determined the efficacy of MI-219 and Nutlin-3 in a number of fresh lymphoma patient samples ex vivo. Over the course of 3 years (2009–2011), analyzable tumor samples obtained from peripheral blood of 11 patients with B-cell lymphoma in leukemic phase were enriched and exposed to increasing concentrations of MI-219 or Nutlin-3 for up to 72 h. Priority of assays performed was dependent upon the total number of available isolated and purified cells and was carried out in the following order: chromosomal karyotyping > determination of p53 status(wild-type [wt] or mutant [mt]) > cell viability post-exposure to Nutlin-3 or MI-219 > Western blot detection of selected p53 target proteins of treated cells. Patient characteristics are shown in Table 1. Eight patients had been clinically diagnosed with small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL) and three with marginal zone lymphoma (MZL). Male: female ratio was 5: 6; and median age was 69 years (range 62–86). Of the eight SLL/CLL patients, six exhibited 13q- and the remaining two expressed trisomy 12. All patients, except one (patient #9) exhibited wt-p53. Patient # 9, with 17p- chromosomal abnormality detected in 9% of cells contained a p53 mutation (Lys132Arg). The group of 11 patients represents indolent non-Hodgkin’s lymphoma associated with a lengthy disease course of slowly proliferating lymphoma cells which eventually leads to enlargement of lymph nodes (lymphadenopathy) and bone marrow failure (manifested as anemia, thrombocytopenia and/or neutropenia) secondary to bone marrow replacement by the lymphoma cells thereby inhibiting bone marrow function. No patient was being actively treated at the time of this study; although several patients had been previously treated.
Effect of HDM2 inhibition in patient-derived B lymphoma cells
Enriched primary B-lymphocytes were analyzed for cell viability. Both MI-219 and Nutlin-3 induced concentration- and time-dependent decreases in cell viability in isolated and purified primary lymphoma cells. A comprehensive biostatistical analysis was performed on n = 11 lymphoma patient samples to determine whether there were significant differences between Nutlin-3 and MI-219 and the extent of their effects on cell viability. The mean cell survival for each combination of drug, concentration, and time is shown in Figure 1 along with standard errors. The results demonstrate that overall, MI-219 is significantly more effective (p < 0.001) at reducing the cell viability of primary lymphoma cells than Nutlin-3.
HDM2 inhibitors activate the p53 pathway in primary lymphoma cells. Both Nutlin-3 and MI-219 induced variable HDM2, p53 and p21 protein expression in purified patient-derived B-lymphocytes (Figure 2). Of special interest is the observation that MI-219, but not Nutlin-3, induced both higher and lower molecular weight species of HDM2. These molecular changes were best captured at 24 h and Western blots for 3 patients with SLL/CLL and 1 with MZL lymphoma are shown in Figure 2A. A statistical analysis summary for changes in the induction of p53-target proteins following exposure to HDM2 SMIs in patient samples is shown in Figure 2B. Cumulatively, MI-219 was more effective than Nutlin-3 (p = 0.001) in the upregulation of p53, p21, and HDM2 protein levels in primary B-lymphoma cells. At 24 h, expression of p53 protein was significantly induced with MI-219 compared to Nutlin-3 at all concentrations and was the largest contributor to the overall significant difference between the two treatments (Figure 2B).
Induction of apoptotic cell death in wt-p53 lymphoma cell lines
A series of experiments were performed using both HDM2 SMIs in two wt-p53 and two mt-p53 lymphoma cell lines. As expected, cell death of mt-p53 cell lines RL and WSU-DLCL2 were not significantly affected by exposure to either HDM2 SMI at concentration up to 10 μM (Figure 3). In wt-p53 WSU-FSCCL and KM-H2 cells, the overall effect of MI-219-induced cell death was significantly greater than that of Nutlin-3. This was seen as early as 24 h following initiation of treatment (p = 0.0001). The apoptotic effect was more evident in the non-Hodgkin’s lymphoma WSU-FSCCL cell line than in the Hodgkin lymphoma KM-H2 cell line. MI-219 treatment in WSU-FSCCL cells led to complete elimination of cells at the end of 72 h at 5 μM and 10 μM concentrations unlike that seen with Nutlin-3 treatment at equivalent concentrations. An increase in the percentage of Annexin V positively stained cells over time reflected the decrease in viability for cell lines expressing wt-p53 (Figure 3; shown as Mean only because of space restriction). A summary of the Annexin V positive data for both wt-p53 cell lines is presented in Table 2.
Data shown in Figure 4A, indicate that neither HDM2 SMI significantly affected the viability of B-lymphocytes derived from normal donors exposed for up to 48 h. The inactive Nutlin-3 enantiomer, Nutlin-3b, did not show any significant reduction in the cell viability of cell lines, demonstrating the selectivity of each HDM2 SMI (Figure 4B).
Evaluation of p53 and p53-dependent target proteins
HDM2 inhibitors upregulate expression of p53-dependent target proteins in wt-p53 cell lines after 24 h (Figure 5). Similar to that observed in patient’s samples, this time point best captured the differences between treatments and demonstrated the effects of MI-219 and Nutlin-3 in modifying the expression of p53, p21, cleaved PARP, cleaved Caspase-3 and Caspase-9 in wt-p53 cell lines. Once again, differences in response to these HDM2 SMIs were evident between the two wt-p53 cell lines (Figure 5A1 and A2). Of note, there was little change in p53 or p21 protein levels in mt-p53 cells (WSU-DLCL2 and RL) and did not show major evidence of PARP and Caspase-3 cleavage (Figure 5B1 and B2). These results show that HDM2 SMIs cannot effectively restore p53 activity to mt-p53 cell lines.
To understand a possible explanation for the enhanced activity of MI-219 over that of Nutlin-3, we determined the IC50s of the HDM2 SMIs using viable cell count as the endpoint in cultures of wt-p53 cell lines (WSU-FSCCL and KM-H2) at equal concentrations for both HDM2 inhibitors. Although the IC50s at 48 h were similar for both agents in wt-p53 WSU-FSCCL cells (2.5 μM for MI-219 and 3 μM for Nutlin-3), the IC50s were significantly different in wt-p53 KM-H2 cells (3 μM for MI-219 and 8 μM for Nutlin-3).
HDM2 inhibition enhances the posttranslational stability of p53
HDM2 inhibition is hypothesized to increase p53 stability by reducing HDM2-mediated degradation. However, p53 stability could also be the result of enhanced p53 protein translation. To demonstrate that upregulation of p53 protein expression shown in the Western blots were the result of HDM2 inhibition by SMIs, the half-life of p53 was monitored. The inhibition of protein synthesis by treatment with 50 μM CHX alone led to a marked decrease of p53 protein expression over time. Blocking protein translation with CHX decreased the turnover of endogenous p53 (Time 0-2 h; ~t1/2 = 0.68 h) (Figure 6). Furthermore, addition of 10 μM of the proteasome inhibitor MG132 alone ameliorates the degradation of p53, thereby enhancing its stabilization.
Treatment with 10 μM Nutlin-3 or 10 μM MI-219 alone for 24th led to an overall increase in p53 protein expression. Whether p53 stability is related to HDM2 inhibition was evaluated by pre-incubation of 10 μM Nutlin-3 or MI-219 for 24 hours in wt-p53 WSU-FSCCL cells followed by treatment with 50 μM CHX at the indicated time points. Blocking protein synthesis after pre-treatment with HDM2 SMI led to an overall increase in p53 protein expression. Intriguingly, MI-219 treatment was more effective in enhancing p53 stability than Nutlin-3. Pre-treatment with 10 μM Nutlin-3 barely extended the p53 stability in the presence of CHX compared to 10 μM Nutlin-3 alone (Time 0-2 h;~ t1/2 =0.86 h) (Figure 6B1) whereas 10 μM MI-219 greatly enhanced the overall stabilization of p53 protein despite the presence of CHX (Figure 6B2).
HDM2 inhibition upregulates p53-dependent genes in wt-p53 lymphoma cell lines
To investigate the effects of HDM2 inhibition on p53 transcriptional regulation, we assessed the effect of SMI-mediated reactivity of p53 to enhance target gene expression levels using qRT-PCR. Additionally, we wanted to determine whether the increase in p53 was the result of newly transcribed p53 mRNA or the accumulation of p53 resulting from the HDM2-p53 disruption. Wt-p53 WSU-FSCCL cells exhibited increases in p53-target genes HDM2, p21, p53AIP1 upon HDM2 inhibition compared to control cells albeit with variable kinetics The results are presented in Figure 7. Of particular importance is that there was virtually no upregulation of p53 mRNA transcripts after treatment with HDM2 SMIs at 24 h, suggesting stabilized p53 protein is the result of HDM2 SMIs and not due to enhanced mRNA transcribed into protein. Interestingly, p53 transcripts mRNA increased 29-fold at 48 h in cells exposed to 10 μM MI-219 compared to a 2.5-fold increase in cells exposed to 10 μM Nutlin-3 for the same time period. Overall, MI-219 treatment demonstrated a surprisingly greater induction of p53-target genes compared to Nutlin-3. There was much higher and more sustained induction of HDM2 mRNA by MI-219 compared with Nutlin-3. Effect on HDM2 transcript peaked at 12 hours but was still remarkable at 24 hour in MI-219-treated cells. Both agents induced upregulation of p21 mRNA in WSU-FSCCL cells with overall higher induction by Nutlin-3 compared with MI-219. However, MI-219 effect was more evident at the earlier time points (12 and 24 hours) and at lower concentrations (2.5 and 5 μM) compared with Nutlin-3. The later induced a delayed induction (48 hours) of p21mRNA. p21 mRNA was increased up to 65-fold at 48 h in cells exposed to 10 μM MI-219 but was increased up to 252-fold at the same time period in cells exposed to 10 μM Nutlin-3. MI-219 was more effective than Nutlin-3 in inducing p53AIP1 mRNA, indicating greater induction of p53-dependent apoptosis genes.
MI-219, but not Nutlin-3, enhances HDM2-medicated autoubiquitination and degradation
Neither class of agents inhibited the E3 ligase function of HDM2 in a cell-free ubiquitination assay (Figure 8A). Autoubiquitination of recombinant His-HDM2 was not inhibited by the addition of Nutlin-3, MI-219 or MI-319 (laboratory grade MI-219) at IC50 or even at much higher (50 μM) concentrations for 1.5 h. Disulfiram (10 μM) completely abrogated autoubiquitination and was included as a negative control.
Identification of HDM2 degraded species from WSU-FSCCL cells was confirmed by immunoprecipitation studies described in Methods. HDM2 from cells exposed to increasing concentrations of Nutlin-3 and MI-219 for 12 h was immunoprecipitated using a1:1 ratio of mouse monoclonal antibodies SMP-14 and D-12 (SMP-14 is known to detect the 60 kDa cleavage product of HDM2) and then immunoblotted (IB) with HDM2 polyclonal antibody (AF1244) to revealed the full length HDM2 in addition to higher molecular weight species (~130 kDa bands [likely autoubiquitinated HDM2]) and ~60 kDa band (the major degraded species of HDM2) (Figure 8B). The intensity of the degraded HDM2 bands were concentration-dependent when obtained from MI-219-treated cells but this was not seen in HDM2 extracted from Nutlin-3-treated cells.
To determine to what extent each of the two HDM2 SMIs induced autoubiquitination of HDM2 in WSU-FSCCL, cells were treated with increasing concentrations of Nutlin-3 and MI-219 for 16 h. Prior to cell harvesting, cells were exposed to MG132 (10 μM) for an additional 15 minutes to preserve the ubiquitinated proteins. HDM2 was immunoprecipitated using antibodies to HDM2 as described above. The blots were then immunoblotted with monoclonal anti-ubiquitin antibody to detect ubiquitinated HDM2. Blots shown in Figure 8C demonstrate that MI-219 induced far greater dose dependent autoubiquitination of HDM2 than Nutlin-3 in this cell line.
These findings suggest that MI-219 but not Nutlin-3 posttranslationally regulates HDM2 protein by inducing autoubiquitination and degradation of itself as a way of compensating for the high levels of HDM2 produced in response to activated p53.
Comparison of MI-219-induced HDM2 autoubiquitination and degradation in KM-H2 versus WSU-FSCCL cell lines
We confirmed our autoubiquitination and degradation observations in the KM-H2 cell line, which had previously appeared to be less sensitive to the effects of both HDM2 inhibitors. As can be seen in Figure 9A, MI-219 induced a more robust response inducing HDM2 autoubiquitination and degradation than Nutlin-3 in both cell lines. However, in KM-H2 cells, HDM2 degradation was delayed compared to that observed in the WSU-FSCCL cell line (Figure 9B).
In unstressed cells, p53 is tightly regulated by HDM2 to ensure that its anti-proliferative and anti-apoptotic activity will not harm normal cells. HDM2 and p53 exist in a finely tuned balanced auto regulatory feedback loop by which the two proteins mutually control their cellular levels . In many cancers, this balance is skewed when overexpression of HDM2 leads to constant suppression of p53 posttranslational modifications (such as phosphorylation, acetylation, methylation) which are necessary for the p53 response to stress. Although the majority of lymphoma tumors retain wt-p53 status, mechanisms to compromise p53 signaling, such as HDM2 overexpression, deletions in p14ARF, and viral oncogenes exist to prevent p53 activation in response to stress or initiate programmed cell death [28–30]. Because of the importance of HDM2 in regulating p53 function, attempts are being made to test the effects of its inhibition in cancer. The discovery of small molecular inhibitors of HDM2-p53 interaction is considered a significant development in the treatment of all types of cancers, particularly those in which the activation of wt- p53 is suppressed. These small molecules are designed to physically sit in the p53 binding pocket of HDM2, thereby preventing HDM2-p53 interaction . HDM2 inhibitors R7112 (Nutlin-3 analog) and JNJ-26854165 (a tryptamine derivative) are currently under clinical evaluation in Phase I studies (NCT00623870, NCT00559533, NCT00676910) and the first results from Phase 1 pharmacokinetic and pharmacodynamic study for JNJ-26854165 or Serdemetan in patients with advanced solid tumors has recently been published . These first results indicate that this agent showed clinical efficacy but at elevated doses some toxic effect were of concern. The authors concluded newer derivatives would provide more optimal results.
We had previously investigated MI-319 in preclinical studies using lymphoma cell lines with encouraging results and found that MI-219, MI-319 and Nutlin-3 exhibited similar activity against the cell lines at the concentrations used in this study . Here, we investigated selected effects of MI-219, a clinical grade spiro-oxindole  against lymphoma cell lines and patient-derived primary indolent non-Hodgkin’s SLL/CLL lymphoma samples. Using the cis-imidazoline inhibitor, Nutlin-3 as a benchmark for comparison, we noted significant differences between the two classes which may have clinical implications. Compared to Nutlin-3, differences could be attributed to enhanced MI-219-induced HDM2 autoubiquitination and degradation which resulted in higher levels of p53 expression and p53 stabilization at equivalent concentrations. Our results indicate that the enhanced MI-219-induced increase in p53 is the result of disruption of the HDM2-p53 complex and released p53 rather than de novo transcribed or translated p53. Further in-depth studies with the WSU-FSCCL cell line demonstrated that MI-219 enhanced efficacy was associated with significantly increased p53-induced p53AIP1 mRNA at the expense of p53-induced HDM2 mRNA at 24 h which was not seen with Nutlin-3. Nutlin-3 induce a greater increase in p53-induced p21 mRNA than MI-219 at 48 h. These results provide evidence that MI-219 can induce cell death pathways earlier and more robustly than Nutlin-3 in cell lines and in patient samples. The enhanced effects of MI-219 could be attributed to several factors including higher binding affinity reported for MI-219 to HDM2 (7-fold higher than Nutlin-3) , differences in chemical structure or differences in solubility between the two agents. Although in our previous study, we found the binding affinity of MI-219 to be only ~3 times higher than that for Nutlin-3, it is highly unlikely that a 3-fold difference is crucial as both HDM2 inhibitors are over 500 times more potent than the natural p53 peptide . Polar groups added to MI-319 to produce the structure of MI-219, increased its solubility for better dispersal in aqueous media and resulted in increased biological activity . The relationship between aqueous solubility and activity has also been demonstrated in the development of another HDM2 SMI, HLI373, which was found to be more potent than its insoluble parent compound HLI 98 s . Three p53 amino acids (Phe19, Trp23 and Leu26) have been found to be essential for binding between the two proteins and are inserted into a deep pocket on the surface of HDM2. Nutlin-3 mimics the p53 binding pocket at these three amino acids. In contrast, MI-219 mimics 4 key binding residues in p53 (Phe 19, Leu22, Trp23 and Leu26) resulting in more optimal hydrogen binding and hydrophobic interaction with HDM2 and this alone may account for its increased efficacy.
While it is known that p53 is induced in response to a number of stimuli including DNA damage, if p53 is bound to HDM2, that response is suppressed. During DNA damage, in normal cells, HDM2 can be phosphorylated at multiple sites which leads to HDM2 ubiquitination, degradation and p53 stabilization [35, 36]. Once again, in cells in which HDM2 is overexpressed, more HDM2 protein can quickly bind to and suppress p53 activation. The focus of our study here was to demonstrate that HDM2 inhibition using HDM2 SMIs would allow free p53 to be activated, if and when necessary, in response to internal as well as external stimuli or stress. Because HDM2 inhibition with these HDM2 SMI does not involve a response to DNA damage, the question remains as to what then initiates the activated p53-induced death pathways in lymphoma cells once p53 suppression is released. Are they the same factors encountered by normal cells and is the response the same for cancer and non-cancerous cells are question for future studies. However, p53 is not the only partner for HDM2. There are more than 30 known proteins that form interactions with HDM2 and include proteins such as NF-κB, p21,pRb, TGFβ-1 as well as others . Their function and significance are not fully understood, although they may have therapeutic implications and have been shown to play a role in cellular responses such as transcriptional regulation, apoptosis and the cell cycle [15, 38].
In addition to disrupting the HDM2-p53 interaction, there is evidence that HDM2 SMIs may induce posttranslational modification of p53. Poyurovsky et al. recently showed that Nutlin-3 induced the modification of the C-terminus of p53 (including acetylation) which may explain its lower efficiency in dissociating p53-HDM2 in vitro . In other studies, using solid tumors, MI-219 was found to target the class II histone deacetylase SIRT 1 (which deacetylates p53 allowing HDM2 to target p53 to ubiquitination) and the Bax-Ku70 interaction . Suppression of Ku70, in theory, would allow pro-apoptotic Bax localization to mitochondria and p53-mediated apoptosis.
Nutlin-3 was one of the first HDM2-SMIs to show significant efficacy in a number of models, thus, there are more published reports on this agent than on MI-219. Bixby et al. confirmed that p53 status was the most important predictor of response to HDM2 SMI in isolated CLL cells studied ex vivo . Results of other studies indicate CLL cells exposed to Nutlin-3 ex vivo in combination with cytotoxic chemotherapeutic agents have demonstrated synergy; while activity of Nutlin-3 as single agent, was modest . Ex vivo studies using isolated multiple myeloma cells indicate that Nutlin-3 was as effective as melphalan without the genotoxic effects . In treatment resistant acute myelogenous leukemia cell, Nutlin-induced apoptosis was mediated by transcriptional activation of pro-apoptotic Bcl-2 family proteins and transcriptional-independent mitochondrial permeabilization via mitochondrial p53 translocation . In Hodgkin lymphoma samples, Nutlin-3 was able to mediate p53 stabilization, cell cycle arrest and initiate the apoptotic death pathway, including Caspase-3 and PARP cleavage.
Differences in response to Nutlin-3 and MI-219 between the WSU-FSCCL and KM-H2 cell lines were seen in our study and may reflect biological differences between Hodgkin’s and non-Hodgkin’s lymphomas which they represent, including different time-frame of response to these two HDM2 SMIs.
This study is one of the first, if not the first, to compare the effects of Nutlin-3 and MI-219 in SLL/CLL samples ex vivo. These SLL/CLL and MZL samples represent slowly dividing tumor cells which have lost the ability to undergo programmed cell death or apoptosis and this leads to bone marrow replacement by lymphoma which impedes its function. Agents which affect mitotic or cell cycle pathways are generally not useful as a therapeutic regimen. Instead, optimal anti-cancer agents are sought to quickly initiate cell death processes for these lymphomas while sparing normal cells. The population studied here exhibits varied genetic characteristics and varied responses to standard treatment and thus, offered an excellent opportunity to test the effects of HDM2 SMIs for treatment of this disease. The results show that the response to MI-219-induced HDM2 autoubiquitination and degradation and associated increase in p53 varied among the studied samples and reflected the genetic diversity which has thwarted the development of a single cure for this group. In other studies, failure of CLL to respond upregulation of p53 have been attributed to polymorphism in the p21 gene , transactive defective spliced variants of the p53 gene , and altered p53-induced effectors .
For extended experimental research studies, we utilized cell lines derived from patients with aggressive forms of NHL. Since these cells do proliferate, effects of anti-cancer agent modifying cell cycle associated proteins (such as p21) can be demonstrated. Further studies in wt-p53 WSU-FSCCL NHL cell line confirmed that MI-219 induced enhance HDM2 autoubiquitination and degradation compared to that in Nutlin-3-treated cells. As this was a consistent finding observed in both wt-p53 cell lines and in patient samples, we demonstrated that none of the HDM2 SMIs (MI-219, MI-319 or Nutlin-3) inhibited recombinant HDM2 ubiquitination and degradation by themselves in a cell-free ubiquitination assay. This indicates that the E3 ligase function of HDM2 is not affected by the inhibitors. The exact mechanism for enhanced MI-219 induced HDM2 autoubiquitination will require further detailed investigation. Possible mechanisms include binding of MI-219, but not Nutlin-3, to HDM2 results in its interaction with one of the many proteins that are known to bind to, and modulate activity of HDM2. Some of these HDM2-interacting proteins have been shown to facilitate or induce HDM2 autoubiquitination and include L11, 14-3-3σ, SCL-BP1, FKBP25, ZNF668, TR3, and RASSF1A [48–54]. In addition, anticancer agents such as Parthenolide accelerate HDM2 autoubiquitination through mechanisms that required ATM and Berberine, which downregulates HDM2 at the posttranslational level through modulation of death domain-associated protein (DAXX) have recently been shown to induce apoptosis [55, 56].
In conclusion, our study reveals for the first time unexpected differences between MI-219 and the prototypical Nutlin-3 in lymphoma cell lines and patient samples. We propose a novel mechanism for MI-219 anti-lymphoma activity that alters the functional activity of HDM2 through enhanced autoubiquitination and degradation. Additionally, this mechanism appears to correspond to biological outcome. Our results provide evidence that different classes of HDM2 SMIs elicit molecular events that extend beyond HDM2-p53 dissociation which may be of biological and potentially therapeutic importance given the oncogenic nature of HDM2. Further investigation of such interaction is pivotal to full realization of the therapeutic potential of these agents in cancer therapy.
Human lymphoma cell lines and patient-derived B-lymphoma cells
WSU-FSCCL and WSU-DLCL2 cell lines were established in our laboratory as previously described [57, 58]. WSU-FSCCL (wt-p53) is a human B-cell follicular small cleaved cell line; WSU-DLCL2 (mt-p53) is a human diffuse large B-cell line. The human Hodgkin lymphoma derived cell line KM-H2 (wt-p53) was obtained from DSMZ (Germany). The human diffuse lymphoma cell line RL (mt-p53) was obtained from the American Type Culture Collection (Manassas, VA). Cells from normal, anonymous healthy donors were isolated from discarded apheresis cones obtained from the Red Cross and were kindly provided by Dr. Martin Bluth, Associate Director of Detroit Medical Center Transfusion Services. Peripheral blood was collected from lymphoma patients in leukemic phase following informed consent in the Lymphoma Clinic at St. John Hospital Van Elslander Cancer Center for clinical examination in accordance with institutional review board (IRB) approval. Ethical consideration for this research study to use the discarded blood after clinical analyses was approved following expedited review by the IRB at Wayne State University School of Medicine.
Patient-derived and normal donor peripheral blood mononuclear cells (PBMCs) were isolated by LymphoPrep density gradient centrifugation (ProGen Biotechnik GmbH, Germany). Monocytes were depleted from the LymphoPrep gradient fraction by allowing cells to adhere to a sterile plastic surface for approximately 1–2 hours at 37°C. Depletion of T-lymphocytes was carried out using 100 μl of Dynabeads pan CD2 (Dynal, Life Technologies, Grand Island, NY). Cells were incubated with prewashed beads for 30 min at 4°C while rotating. T-cells were depleted using the DynaMag as a magnetic retrieval device according to the manufacturer’s protocol. The unbound, negatively selected, highly purified B-cell populations were recovered by aspiration and used for functional assays. FACS analysis confirmed non-B-cell depletion and verified that the recovered cell population contained >90% B-lymphocytes. All cells were maintained in suspension in RPMI 1640 medium supplemented with 10% fetal bovine serum (Denville Scientific, Denville, NJ) and 1% Penicillin/Streptomycin (Invitrogen, Carlsbad, CA) at 37°C in a 5% CO2 humidified incubator.
Reagents and drug treatments
MI-219 (Ascenta Therapeutics, Malvern, PA) was synthesized using methods previously published [59, 60]. Disulfiram (a RING-finger ubiquitin E3 ligase inhibitor), Nutlin-3 (Sigma Aldrich, St. Louis, MO), its 150-times less active enantiomer (+)-Nutlin-3b (Cayman Chemical, Ann Arbor, MI), and MI-219 were dissolved in 100% DMSO as 10 mM stock solution. The proteasomal inhibitor, MG132 (Cayman Chemical) and cycloheximide (Sigma) were dissolved in 100% DMSO as 100 mM stock solution. Reagents were further diluted in sterile water immediately prior to adding to cultures to obtain the desired final concentration.
Identification of p53 status
p53 cDNA sequencing was used to identify the p53 status of the patient samples. Genomic DNA was extracted from approximately 1 × 106 purified B-lymphocytes recovered from each patient sample using a ZR-Duet™ DNA/RNA MiniPrep kit (Zymogen Biotech). Samples were quantitated by UV absorption at 260 nm and 200 ng was used in each PCR amplification reaction. Two primer sets were used to amplify p53 coding exons 5–9 as previously described [26, 61]. These exons have been identified as the DNA-binding region which contains approximately 90% of all known p53 mutations . Amplified cDNA PCR products were analyzed by agarose gel electrophoresis and purified using Wizard SV Gel/PCR Cleanup kit (Promega, Madison, WI). Two primers, one from each primer set, and 200 ng of the PCR products were sent to GeneWiz, Inc. (South Plainfield, NJ) for DNA sequencing. cDNA sequences were analyzed for p53 mutations by comparing the obtained sequences to BLAST wt-p53 coding sequence: NCBI Reference Sequence: NM_000546.4.
Characteristics of the patient’s lymphoma were made available through the Lymphoma Clinic at (St. John’s Hospital) and FISH analyses of chromosomal re-arrangements were provided by Dr. Steve Buck at Children’s Hospital of Michigan Flow Cytometry Core.
Cell viability assays
Cell lines and patient derived cells were seeded at a density of 2 x 105/ml and allowed to adapt overnight before being exposed to varying concentrations of Nutlin-3 or MI-219 the following day. Control cells were treated with equal volume of DMSO for a final concentration of 0.1%. 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reagent (Sigma) was added 24, 48 or 72 hours later to halt reactions and monitor cell viability in cell lines. Purple formazan crystals were solubilized in DMSO and absorbance was read in a plate reader at 540 nM.3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) reagent (Sigma) was added 24, 48 or 72 hours later to halt reactions and monitor cell viability in cell lines. Purple formazan crystals were solubilized in DMSO and absorbance was read in a plate reader at 540 nM. Cell viability was also determined at for patient samples using Trypan Blue (0.4%; Sigma) Exclusion. The IC50 was assessed as 50% inhibitory concentration compared to vehicle-treated (control). Data are represented as Mean ± SE. of at least three independent experiments performed in duplicate for each cell line.
Biostatistical analyses assessing percent survival of patient tumor samples were replicated for a minimum of 2 and a maximum of 6 times for each patient at each drug, dose, and time point. Cell survival for the cumulative patient cohort ranged from 0% to 100%. The quantile-quantile plot for patient samples indicated that the observed data had a longer right tail than would be expected if the data were normally distributed. Nonetheless, a mixed effects analysis of variance was used because the violation was not outrageously extreme and because no better alternative could be found given the experimental design. In the mixed effects model drug, concentration and time were defined as fixed effects; patient and replication were defined as random effects. Holm’s procedure was used to adjust for multiple comparisons.
cDNA preparation and quantitative real-time PCR to detect the induction of p53-target genes
Total RNA was extracted from treated and control lymphoma cells using the PureLink™ RNA Mini Kit (Invitrogen). Total RNA was quantified by NanoDrop and 1 μg of each sample was reverse-transcribed using the SuperScript® VILO™ cDNA synthesis kit according to the manufacurer’s instructions (Invitrogen). The resulting cDNA preparations were then cleaned of excess enzyme with Wizard SV Gel/PCR Cleanup kit (Promega). Real time PCR amplifications were conducted in a 10 μl reaction volume using the Roche LightCycler® 480 SYBR Green I Master (Roche, Pleasanton, CA) according to manufacturer’s protocol. 100 ng cDNA samples were used for each reaction and mixed with Quanti Tect Primers (Qiagen) to amplify p53, HDM2, p21, p53AIP1 using GAPDH as the internal standard. Qiagen priority patened primer sequences verified and standardized for specific gene products were those supplied with Qiagen Tect sets; (http://www.qiagen.com). Reactions were carried out in a 384-well microtiter plate using the LightCycler® 480 System (Roche). Two independent drug treatments per sample were performed in triplicate and each reaction was repeated at least once to ensure accuracy. The PCR cycle number at threshold (CT) was used for the comparison. Baseline gene expression and gene expression post treatment were quantified by qRT-PCR relative to GAPDH using the ΔΔCt method and expressed as fold induction of gene expression relative to that in the untreated control . Values represent mean ± SE of two independent experiments performed in triplicate. Statistical analyses were performed by two-way ANOVA using GraphPad Prism v. 4.0.
Treated cells were collected by centrifugation, washed twice with sterile PBS, and solubilized in M-PER lysis buffer (ThermoScientific, Rockford, IL) consisting of a cocktail of protease and phosphatase inhibitors (ThermoScientific). The concentration of total cell lysate was quantified by BCA protein method (Pierce; Thermo Scientific). Cellular lysates (50 μg of protein) were fractionated onto 14% or 4-20% Tris-Glycine SDS-PAGE gels, transferred onto PVDF membrane, and probed with primary antibodies to p53 (DO-1; Santa Cruz Biotechnology, Inc, Santa Cruz, CA), HDM2 (AF1244; R and D Systems, Minneapolis, MN); p21 (2947), cleaved PARP (5625), cleaved caspase-3 (9664) and ubiquitin (3936) from Cell Signaling Technology, Danvers, MA, with GAPDH (Trevigen, Gaithersburg, MD) as the internal control. Secondary antibodies were anti-mouse or anti-rabbit conjugated to HRP (Jackson ImmunoResearch). Proteins were visualized using chemiluminescence substrate reagents.
For statistical analyses of data for primary lymphoma cells, relative density was selected as the endpoint. It was defined as the ratio of the absolute density for a given protein treated with a given drug, at a given concentration, for a specific time, for a specific patient to the absolute density of GAPDH under the same conditions. Fixed effects linear models were used with drugs, Nutlin-3 and MI-219 concentrations, proteins, and time as fixed effects and patient as the random effect. Evaluation of the shape of the frequency distribution of relative density indicated that a natural log transformation was required to meet the assumptions of the statistical tests. Holm’s procedure was used to adjust for multiple comparisons.
Cell-free HDM2 autoubiquitination assay
Cell free autoubiquitination assays were performed using 200 ng of recombinant His-HDM2 in the presence or absence of E2-conjugatng enzyme, UbcH5b, recombinant human E1 (Boston Biochem, Cambridge, MA), in the presence or absence of HDM2 SMIs. Final concentration of drug was IC50 or 50 μM for Nutlin-3, MI-219, and MI-319 diluted in 30 μL reaction volume. Disulfiram (10 μM), an ubiquitin E3 ligase inhibitor was used as a control. Samples were incubated for 1.5 hours at 30°C. The reaction was stopped with the addition of 10 μl of 3X SDS loading dye, boiled for 5 minutes, separated on a 4-20% Tris-Glycine gradient gel (Invitrogen), and then immunoblotted with anti-ubiquitin antibody.
WSU-FSCCL or KM-H2 cells were treated with Nutlin-3 or MI-219 for specified period of time, harvested and lysed as described above. Total cellular lysate (1 mg) was incubated with 5 μg primary antibody overnight (a 1: 1 ratio of HDM2 antibodies SMP-14 and D-12, Santa Cruz) rotating at 4°C (SMP-14 is known to detect the 60 kDa degraded product of HDM2). The following day, Protein G agarose beads (Millipore) were added to each sample and incubated at 4°C for an additional 4 hours. Agarose bead-linked antibody: antigen complexes were collected by centrifugation, washed 3 times with 1× PBS prior to the addition of 3× SDS-PAGE loading dye, denatured at 95°C for 5 min, and centrifuged briefly. The solubilized immunoprecipitates were separated on a 4-20% Tris-Glycine gradient gel and immunoblot (IB) with HDM2 polyclonal antibody (AF1244). Ubiquitin antibody was used for co-immunoprecipitation.
Data analysis and statistical significance
Statistical analyses were performed by two-way ANOVA unpaired two-tailed GraphPad Prism v. 4.0 or unpaired two-tailed t test using Microsoft Excel. ImageJ densitometry software (Version 1.45, US National Institutes of Health) was used for quantification of Western blot bands. Selected bands were quantified based on their relative integrated intensities, calculated as the product of the selected pixel area and the mean gray value for those pixels normalized to internal control (GAPDH). Fold increase or decrease was calculated by standardizing each treatment as a ratio to the control. Additional data analysis and statistical methods are described in different sections of the Materials and Methods above. Statistical significance was set at p < 0.05 for all data comparisons.
Grant support: Ruth L. Kirschstein National Research Service Award T32-CA009531 (A. M. Sosin).
Chronic lymphocytic leukemia
Human Double Minute 2
p53 apoptosis-inducing protein 1
Peripheral blood mononuclear cells
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 2012, 62: 10-29. 10.3322/caac.20138.
Collavin L, Lunardi A, Del Sal G: p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010, 17: 901-911. 10.1038/cdd.2010.35.
Prives C, Hall PA: The p53 pathway. J Pathol. 1999, 187: 112-126. 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3.
Oren M: Regulation of the p53 tumor suppressor protein. J Biol Chem. 1999, 274: 36031-36034. 10.1074/jbc.274.51.36031.
Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene. 2005, 24: 2899-2908. 10.1038/sj.onc.1208615.
Hollstein M, Sidransky D, Vogelstein B, Harris CC: p53 mutations in human cancers. Science. 1991, 253: 49-53. 10.1126/science.1905840.
Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M, Kolitz J, Broome JD: Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 1997, 90: 4078-4091.
Keshelava N, Zuo JJ, Chen P, Waidyaratne SN, Luna MC, Gomer CJ, Triche TJ, Reynolds CP: Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 2001, 61: 6185-6193.
Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997, 75: 230-235. 10.1038/bjc.1997.38.
Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, Yamashiro K, Dosaka-Akita H, Nishimura M: Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003, 94: 394-399. 10.1111/j.1349-7006.2003.tb01453.x.
Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature. 1993, 362: 857-860. 10.1038/362857a0.
Haupt Y, Maya R, Kazaz A, Oren M: Mdm2 promotes the rapid degradation of p53. Nature. 1997, 387: 296-299. 10.1038/387296a0.
Momand J, Wu HH, Dasgupta G: MDM2–master regulator of the p53 tumor suppressor protein. Gene. 2000, 242: 15-29. 10.1016/S0378-1119(99)00487-4.
Iwakuma T, Lozano G: MDM2, an introduction. Mol Cancer Res. 2003, 1: 993-1000.
Honda R, Yasuda H: Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene. 2000, 19: 1473-1476. 10.1038/sj.onc.1203464.
Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM: Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000, 275: 8945-8951. 10.1074/jbc.275.12.8945.
Stommel JM, Wahl GM: A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle. 2005, 4: 411-417. 10.4161/cc.4.3.1522.
Stommel JM, Wahl GM: Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 2004, 23: 1547-1556. 10.1038/sj.emboj.7600145.
Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H: The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood. 1994, 84: 3158-3165.
Chilosi M, Doglioni C, Menestrina F, Montagna L, Rigo A, Lestani M, Barbareschi M, Scarpa A, Mariuzzi GM, Pizzolo G: Abnormal expression of the p53-binding protein MDM2 in Hodgkin's disease. Blood. 1994, 84: 4295-4300.
Zhang Wang H: MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des. 2000, 6: 393-416. 10.2174/1381612003400911.
Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007, 28: 622-629. 10.1002/humu.20495.
Mitani N, Niwa Y, Okamoto Y: Surveyor nuclease-based detection of p53 gene mutations in haematological malignancy. Ann Clin Biochem. 2007, 44: 557-559. 10.1258/000456307782268174.
Kojima K, Burks JK, Arts J, Andreeff M: The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010, 9: 2545-2557. 10.1158/1535-7163.MCT-10-0337.
Mohammad RM, Wu J, Azmi AS, Aboukameel A, Sosin A, Wu S, Yang D, Wang S, Al-Katib AM: An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol Cancer. 2009, 8: 115-10.1186/1476-4598-8-115.
Wu X, Bayle JH, Olson D, Levine AJ: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 1993, 7: 1126-1132. 10.1101/gad.7.7a.1126.
Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408: 307-310. 10.1038/35042675.
Chene P: Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat Rev Cancer. 2003, 3: 102-109. 10.1038/nrc991.
Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer. 2002, 2: 594-604. 10.1038/nrc864.
Shangary S, Wang S: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 2009, 49: 223-241. 10.1146/annurev.pharmtox.48.113006.094723.
Tabernero J, Dirix L, Schoffski P, Cervantes A, Lopez-Martin JA, Capdevila J, van Beijsterveldt L, Platero S, Hall B, Yuan Z: A phase I first-in-human pharmacokinetic and pharmacodynamic study of serdemetan in patients with advanced solid tumors. Clin Cancer Res. 2011, 17: 6313-6321. 10.1158/1078-0432.CCR-11-1101.
Shangary S, Qin D, McEachern D, Liu M, Miller RS, Qiu S, Nikolovska-Coleska Z, Ding K, Wang G, Chen J: Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci U S A. 2008, 105: 3933-3938. 10.1073/pnas.0708917105.
Kitagaki J, Agama KK, Pommier Y, Yang Y, Weissman AM: Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2. Mol Cancer Ther. 2008, 7: 2445-2454. 10.1158/1535-7163.MCT-08-0063.
Dias SS, Hogan C, Ochocka AM, Meek DW: Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover. FEBS Lett. 2009, 583: 3543-3548. 10.1016/j.febslet.2009.09.057.
Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ, Vousden KH: Phosphorylation of HDM2 by Akt. Oncogene. 2002, 21: 1955-1962. 10.1038/sj.onc.1205276.
Azmi AS, Beck FW, Sarkar FH, Mohammad RM: Network perspectives on HDM2 inhibitor chemotherapy combinations. Curr Pharm Des. 2011, 17: 640-652. 10.2174/138161211795222612.
Moll UM, Petrenko O: The MDM2-p53 interaction. Mol Cancer Res. 2003, 1: 1001-1008.
Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A: The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol. 2010, 17: 982-989. 10.1038/nsmb.1872.
Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM: Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy. Curr Cancer Drug Targets. 2010, 10: 319-331. 10.2174/156800910791190229.
Bixby D, Kujawski L, Wang S, Malek SN: The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to MDM2 inhibitor-mediated apoptosis. Cell Cycle. 2008, 7: 971-979. 10.4161/cc.7.8.5754.
Coll-Mulet L, Iglesias-Serret D, Santidrian AF, Cosialls AM, de Frias M, Castano E, Campas C, Barragan M, de Sevilla AF, Domingo A: MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood. 2006, 107: 4109-4114. 10.1182/blood-2005-08-3273.
Stuhmer T, Chatterjee M, Hildebrandt M, Herrmann P, Gollasch H, Gerecke C, Theurich S, Cigliano L, Manz RA, Daniel PT: Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. Blood. 2005, 106: 3609-3617. 10.1182/blood-2005-04-1489.
Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M: MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005, 106: 3150-3159. 10.1182/blood-2005-02-0553.
Johnson GG, Sherrington PD, Carter A, Lin K, Liloglou T, Field JK, Pettitt AR: A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. Cancer Res. 2009, 69: 5210-5217. 10.1158/0008-5472.CAN-09-0627.
Pekova S, Cmejla R, Smolej L, Kozak T, Spacek M, Prucha M: Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia. Leuk Res. 2008, 32: 395-400. 10.1016/j.leukres.2007.06.022.
Zauli G, di Iasio MG, Secchiero P: Dal Bo M, Marconi D, Bomben R, Del Poeta G, Gattei V: Exposure of B cell chronic lymphocytic leukemia (B-CLL) cells to nutlin-3 induces a characteristic gene expression profile, which correlates with nutlin-3-mediated cytotoxicity. Curr Cancer Drug Targets. 2009, 9: 510-518. 10.2174/156800909788486777.
Dai MS, Shi D, Jin Y, Sun XX, Zhang Y, Grossman SR, Lu H: Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism. J Biol Chem. 2006, 281: 24304-24313. 10.1074/jbc.M602596200.
Lee MH, Lozano G: Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol. 2006, 16: 225-234. 10.1016/j.semcancer.2006.03.009.
Yan J, Zhang D, Di Y, Shi H, Rao H, Huo K: A newly identified Pirh2 substrate SCYL1-BP1 can bind to MDM2 and accelerate MDM2 self-ubiquitination. FEBS Lett. 2010, 584: 3275-3278. 10.1016/j.febslet.2010.06.027.
Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F, Meek D: FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett. 2009, 583: 621-626. 10.1016/j.febslet.2009.01.009.
Hu R, Peng G, Dai H, Breuer EK, Stemke-Hale K, Li K, Gonzalez-Angulo AM, Mills GB, Lin SY: ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 2011, 71: 6524-6534. 10.1158/0008-5472.CAN-11-0853.
Zhao BX, Chen HZ, Lei NZ, Li GD, Zhao WX, Zhan YY, Liu B, Lin SC, Wu Q: p53 mediates the negative regulation of MDM2 by orphan receptor TR3. EMBO J. 2006, 25: 5703-5715. 10.1038/sj.emboj.7601435.
Song MS, Song SJ, Kim SY, Oh HJ, Lim DS: The tumour suppressor RASSF1A promotes MDM2 self-ubiquitination by disrupting the MDM2-DAXX-HAUSP complex. EMBO J. 2008, 27: 1863-1874. 10.1038/emboj.2008.115.
Gopal YN, Chanchorn E, Van Dyke MW: Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther. 2009, 8: 552-562. 10.1158/1535-7163.MCT-08-0661.
Zhang X, Gu L, Li J, Shah N, He J, Yang L, Hu Q, Zhou M: Degradation of MDM2 by the interaction between berberine and DAXX leads to potent apoptosis in MDM2-overexpressing cancer cells. Cancer Res. 2010, 70: 9895-9904. 10.1158/0008-5472.CAN-10-1546.
Mohammad RM, Mohamed AN, Smith MR: Jawadi NS, al-Katib A: A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet. 1993, 70: 62-67. 10.1016/0165-4608(93)90132-6.
Al-Katib AM, Smith MR, Kamanda WS, Pettit GR, Hamdan M, Mohamed AN, Chelladurai B, Mohammad RM: Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res. 1998, 4: 1305-1314.
Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, Gao W, Qin D, Stuckey J, Krajewski K: Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem. 2006, 49: 3432-3435. 10.1021/jm051122a.
Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, Stuckey J, Krajewski K, Roller PP, Tomita Y: Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc. 2005, 127: 10130-10131. 10.1021/ja051147z.
Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, Erba H, Shedden K, Wang S, Malek SN: Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood. 2008, 111: 1584-1593.
Hainaut P, Hollstein M: p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000, 77: 81-137.
Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.
The authors wish to thank Alden Wong and Dr. Jessica Back at the Karmanos Cancer Institute Flow Cytometry Core Facility for running the flow cytometric experiments. Appreciation is also extended to Dr. Larry Matherly at the Karmanos Cancer Institute for the use of qRT-PCR instrumentation. This work was graciously supported by an award from the Ruth L. Kirschstein National Research Service (T32-CA009531) to A.M. Sosin.
The authors have no conflict of interest to declare and none has any commercial interest in any of the agents used in this study.
AMS designed and carried out all experiments, correlated and analyzed the resulting data, organized and prepared the manuscript for publication. AMB provided the reagents and supervised the cell-free ubiquitination assays that AMS performed in her lab as well as interpretation of data. AS provided technical assistance to AMS in carrying out experiments. JA provided biostatistical analyses of the primary cell data. RMM provided direction, guidance, interpretation and critiquing of data. AMA provided suggestions, additional funding, lymphoma patient samples and encouragement for the overall project. All authors read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
About this article
Cite this article
Sosin, A.M., Burger, A.M., Siddiqi, A. et al. HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas. J Hematol Oncol 5, 57 (2012). https://doi.org/10.1186/1756-8722-5-57
- B-cell lymphoma
- Small-molecule inhibitor